Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
BIAF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.18
vs -0.54
Q2.23
N/A
-0.20
vs -0.18
Q3.23
N/A
-0.26
vs -1.10
Q4.23
N/A
-0.26
vs -0.20
Q1.24
N/A
-0.26
vs -0.18
Q2.24
N/A
-0.19
vs -0.20
Q3.24
N/A
-0.16
vs -0.26
Q4.24
N/A
-0.21
vs -0.26
Q1.25
N/A
-0.16
vs -0.26
Q2.25
N/A
-0.12
vs -0.19
Sales Growth
YoY
Current
Estimates
Q1.23
NA
921 vs NA
Q2.23
+1411%
19.7K vs 1.3K
Q3.23
+25855%
298.5K vs 1.1K
Q4.23
+94246%
2.2M vs 2.3K
Q1.24
+261180%
2.4M vs 921
Q2.24
+12047%
2.4M vs 19.7K
Q3.24
+687%
2.4M vs 298.5K
Q4.24
0%
2.2M vs 2.2M
Q1.25
-12%
2.1M vs 2.4M
Q2.25
-50%
1.2M vs 2.4M
Return on Equity
QoQ
Q1.23
-16%
-0.16
vs -0.15
Q2.23
-21%
-0.21
vs -0.16
Q3.23
-33%
-0.33
vs -0.21
Q4.23
-49%
-0.49
vs -0.33
Q1.24
-37%
-0.37
vs -0.49
Q2.24
-61%
-0.61
vs -0.37
Q3.24
-64%
-0.64
vs -0.61
Q4.24
-114%
-1.14
vs -0.64
Institutionnal Ownership
Forecast
174%2025-Revenue
-181%2025-EPS
61%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Hold
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
businesswire.com
9 hours ago
zacks.com
13 hours ago
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
NASDAQ
Unprofitable
Unprofitable
-0.01Â ( -2.54%)
Relative Strenght
5
Volume Buzz
-99%
Earning Acce
No
Dist 52w H.
83%Relative Strength
BIAF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics